KPV (Lys–Pro–Val) is a short peptide derived from alpha-MSH, known for its potent anti-inflammatory properties without melanotropic or hormonal side effects. It has shown significant promise in research on colitis, IBD, wound healing, and cytokine regulation.
In preclinical models, KPV:
Reduced intestinal inflammation via PepT1 uptake
Suppressed TNF-α, IL-1β, and IL-6 expression
Improved outcomes in ulcerative colitis and epithelial barrier function
Demonstrated effective transdermal delivery for topical inflammation
With a small molecular structure and high tolerability, KPV is a flexible research compound suitable for multiple delivery platforms and inflammation pathways.
KPV (Lys–Pro–Val) is a short peptide derived from alpha-MSH, known for its potent anti-inflammatory properties without melanotropic or hormonal side effects. It has shown significant promise in research on colitis, IBD, wound healing, and cytokine regulation.
In preclinical models, KPV:
Reduced intestinal inflammation via PepT1 uptake
Suppressed TNF-α, IL-1β, and IL-6 expression
Improved outcomes in ulcerative colitis and epithelial barrier function
Demonstrated effective transdermal delivery for topical inflammation
With a small molecular structure and high tolerability, KPV is a flexible research compound suitable for multiple delivery platforms and inflammation pathways.